OBJECTIVE: To determine outcome of @entity521 ( @entity521 ) in @entity1 under 18  mo of age who had been treated with national protocols. METHODS: The characteristics and treatment outcomes of 27 @entity1 were evaluated retrospectively. RESULTS: The event-free survival (EFS) at 60 and 108  mo were 84.7  %        7.7 and 72.6  %        7.7, respectively. The @entity1349 ( @entity1349 ) was 91.7  %        8 at 108  mo. The only significant risk factor for @entity1349 in @entity1 with @entity521 was the treatment response at the end of therapy (p   =   0.001). "Wait and see" policy was applied to two @entity1 with low risk @entity521 and one @entity1 with stage 4S @entity521 and all 3 of these @entity1 have been in remission at last followup. Four of the five @entity1 with @entity4180 -amplified @entity521 were alive at a median follow-up time of 54  mo (range: 5-108  mo). CONCLUSIONS: The EFS and @entity1349 of the present group were similar to that of the previous series which included @entity1 under 18  mo of age with @entity521 . Well known prognostic factors did not affect EFS and @entity1349 significantly; this may be related to the retrospective design of the present study and the small number of @entity1 reviewed. High survival rate in @entity1 with @entity4180 -amplified @entity5 suggests the difference in the biology of @entity1 @entity521 .

Outcome in XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants', 'infant'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma', 'NBL'] @entity4180 :: ('4613', 'Gene') :: ['MYCN'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity521 :: (MESH:D009447,Disease) :: ['Neuroblastoma']
